USA vs China vs India: Where Supplements Are Really Made

There is no single best country, because "manufacturing" is really two separate industries stacked on top of each other. China wins on synthetic commodity actives made at enormous scale. India wins on botanicals, standardized extracts and pharma-grade GMP discipline, which is why so much of the herbal supplement and generic drug world runs through it. The United States wins on jurisdiction — an FDA-inspectable plant, legal recourse, a defensible Made-in-USA claim and restocks measured in weeks instead of months.

The brands that get burned are the ones who think they made a country decision when they only made a bottling decision. For the two-country version of this comparison see our India vs China manufacturing guide, and for the domestic-versus-offshore trade-off read US manufacturer vs overseas.

Every finished supplement has an ingredient origin and a finishing origin, and they are almost never the same country. The label tells you the second one. Your quality risk, your tariff exposure and your recall exposure mostly live in the first.

Dismissing China is a mistake — the category simply would not exist at current prices without it. Decades of state-backed capital expenditure produced fermentation and synthesis capacity at a scale nobody else matches.

• Synthetic and fermented vitamins. Ascorbic acid, B-vitamins, vitamin E and vitamin D3 are dominated by Chinese production; US feed and food industry testimony has described vitamin D3 supply as effectively China-dependent.
• Amino acids. Lysine, methionine, threonine, BCAAs and most sports-nutrition aminos come from large-scale fermentation concentrated in China, with Southeast Asia and Brazil as the secondary base.
• Excipients and hardware. Capsule shells, packaging components, scoops, sachets and bottles — the unglamorous 30% of your bill of materials.
• Price per kilogram at volume. On stable commodity inputs, nobody is cheaper, and pretending otherwise leads to a formula you cannot afford to sell.

The trade-offs are real too: tariff volatility that can reprice a SKU mid-launch, longer verification chains on adulteration-prone materials, and cross-border recourse that is slow when a lot fails. None of that is disqualifying — it is a reason to test every incoming lot rather than to trust a certificate.

This is the part of the map most brands know least, and it is the part that decides whether an herbal formula is credible. India's position in botanicals and pharmaceuticals is not an accident of cheap labor — it is four separate advantages compounding over fifty years.

• 1. The plants actually grow there. Ashwagandha, turmeric, boswellia, bacopa, holy basil, amla, moringa, gymnema, guggul and shatavari are native or long-cultivated Indian crops. Agronomy, harvest timing, drying infrastructure and farmer networks are established at commercial scale, and the plant material never travels far before extraction — which matters because degradation starts at harvest.
• 2. Three thousand years of documented use. Ayurveda is not folklore in a regulatory sense: the plant part, the harvest window, the preparation method and the traditional dose are written down. That documentation is why a Western brand can substantiate an ashwagandha root extract far more easily than an obscure botanical with no monograph behind it.
• 3. A real regulatory framework for botanicals. The Ayurvedic Pharmacopoeia of India and the Ministry of AYUSH give identity standards, quality parameters and licensing for herbal material. Most botanical-exporting countries have nothing comparable, which is exactly why unstandardized material from elsewhere is so much harder to qualify.
• 4. The standardized extract industry was built there. The shift from "dried herb powder" to "extract standardized to 5% withanolides" happened in Indian labs. A large share of the branded, clinically studied botanical ingredients Western brands pay a premium for are Indian-developed, with marker-compound specs, HPLC methods and published human trials behind them.

Layered on top of that is the pharmaceutical industry, and this is the point brands usually miss. India is the third-largest pharmaceutical producer in the world by volume, supplies over 20% of global generic exports, and — per CareEdge and industry reporting — has the highest number of USFDA-approved manufacturing plants outside the United States, with roughly 45% of US generic medicines by volume coming from Indian production. Indian pharma exports reached about USD 30.5 billion in FY25, a near sixteen-fold increase since 2000–01.

The honest caveat: India's range is wide. The same country contains export plants that pass USFDA inspection and domestic-only operations that would not survive one. Adulteration of high-value extracts — curcumin cut with synthetic dyes, ashwagandha bulked with leaf material when the claim is root — is a genuine and documented risk. That is an argument for identity testing every lot, not for sourcing your botanicals somewhere they do not grow. Our ashwagandha manufacturing guide and ingredient sourcing guide cover the specific tests.

US finishing is not about ingredient purity by nationality. It is about where the accountability sits when something goes wrong, and about how fast you can respond when something goes right.

• Jurisdiction. An FDA-inspectable facility on US soil, with an inspection history you can look up and a legal system you can actually use.
• 21 CFR Part 111 in practice. Written specifications, identity testing on every incoming dietary ingredient, batch records and finished-product verification — applied to material regardless of where it originated.
• Restock speed. 14–21 days domestically versus 8–14 weeks by ocean. A viral SKU that stocks out for three months is usually just dead.
• Label and claim control. A packaging correction or a Supplement Facts fix is a scheduling conversation, not a new import cycle. See our Made-in-USA labeling guide.
• Channel credibility. Amazon compliance reviews, retail buyer questionnaires and third-party testing accounts all move faster when the finishing plant is domestic and documented.

After a few production cycles, nearly every brand converges on the same structure — and it is not "pick a country".

• Botanical and herbal actives from India. Standardized extracts with marker-compound specs, an identity method and, where the claim needs it, a clinical dossier.
• Commodity synthetics from the best-qualified supplier, which is frequently China and increasingly Europe or India depending on the molecule and the current duty stack.
• Finishing, testing and release in the US under 21 CFR Part 111 — blending, encapsulation, gummy depositing or filling, with per-lot identity, potency, micro and heavy-metals testing.
• Domestic 3PL and inventory buffer so a marketplace spike is an opportunity rather than a stockout.
• A qualified second source for every critical active, because single-sourcing a botanical is how a tariff change or a bad monsoon becomes your problem.

That is precisely how Peakfinity Labs is structured. We have been manufacturing since 1980 with deep Indian botanical sourcing relationships and a 375,000+ sq ft company-owned production base, and every lot is verified and released against US requirements before it becomes your inventory.

• "Show me the identity method for this active." HPLC with a marker compound, or a supplier certificate taken on faith? Only one of those is testing.
• "What is the country of origin of every active in my formula?" A manufacturer who cannot answer per ingredient does not know your supply chain either.
• "What is your heavy-metals limit and do you test per lot?" Botanicals concentrate soil metals; per-lot is the only defensible answer, especially for California Prop 65.
• "Can I see your FDA registration and last inspection outcome?" Applies equally to a US, Indian or Chinese export facility.
• "What is the sampling plan for my run?" Ask before production, in writing — not for the certificate afterward.
• "What is my landed cost, not my unit cost?" FOB plus duty, freight, customs handling, financing and inventory float. That number decides the country question far more often than the quote does.

China built the world's synthetic ingredient capacity. India built the world's botanical extract and generic pharmaceutical capacity, and with it a GMP culture forged under USFDA inspection. The United States offers the jurisdiction, verification and speed that turn those inputs into a product you can defend to a regulator, a retailer and a customer.

The winning answer is not a flag. It is Indian-standardized botanicals, globally-sourced synthetics from qualified suppliers, and US finishing with per-lot testing — one accountable partner holding the whole chain together.